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Abstract
Parkinson’s

disease

neurodegenerative

(PD)

disorder,

is

the

second

characterized

by

most

common

abnormal

progressive

accumulation

of

interneuronal inclusions of α-synuclein (α-syn) known as Lewy bodies (LBs) and
Lewy neurites (LNs), and significant loss of dopamine neurons in the substantia
nigra pars compacta (SNc) region of the brain. Recent evidence suggests that
intrastriatal inoculation of α-syn Preformed Fibril (PFF) into mouse induces PD
like LBs and LNs pathology formed by aggregated α-syn in anatomically
interconnected brain regions which needs several months of incubation to develop
the pathology. In the present study, we have evaluated the effect of different doses
of 1-methyl, 4-phenyl, 1,2,3,6 tetrahydropyridine (MPTP) in triggering endogenous
alpha-synuclein spreading when inoculated with human wild type (WT) α-syn
preformed fibrils. We have found that single injection of human WT α-syn
preformed fibrils into the striatum region of the brain induces the propagation of
phosphorylated α-syn (pS129) to the SNpc within short period of time.
Interestingly, injection of low dose of MPTP (10 mg/kg.b.wt) 6 weeks after postinoculation of α-syn preformed fibrils further enhances the spreading where high
dose of MPTP (25 mg/kg.b.wt.) reduces the spreading. After intrastriatal injection
of α-Syn preformed fibrils, low dose of MPTP enhanced the pathological
accumulation of phosphorylated α-syn (pS129) in the ipsilateral side. The majority
of the accumulated α-syn were proteinase k resistant which recognized by
conformational specific antibody of α-syn. Furthermore, we have found that
injection of α-syn preformed fibrils alone causes only 12% dopaminergic neuronal
loss while in presence of low dose of MPTP it causes 33% in comparison to saline
injected control mice (100%). Combination of α-synuclein preformed fibril and low
dose of MPTP also causes deficit in motor coordination. Noteworthy to mention
that low dose of MPTP alone does not cause significant dopaminergic cells death
when comparing to saline treated group. Interestingly, animals that receive
combination of α-synuclein preformed fibril and high dose of MPTP show a
massive activation of glial cells. However, they show a decrease in α-synuclein
spreading and the majority of the detectable α-syn was found in the nucleus.
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Therefore, our results suggest that human WT α-synuclein preformed fibrils in
combination with low dose of MPTP increases the pathological conversion and the
propagation of endogenous α-syn as well as neurodegeneration within very short
period of time. Our presented model may be used to study the mechanism of α-syn
propagation and for screening of potential drug for PD.

Keywords: Parkinson’s Disease, α-synuclein, Preformed fibril (PFF), MPTP, Lewy
body.
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)Title and Abstract (in Arabic

تأثير مادة الـ  MPTPعلى انتشار و تراكم و سمية بروتين األلفا سينوكليين في
الفئران المحقونة بألياف األلفا سينوكلين مسبقة التحضير
الملخص

عا ،ويتميز بتراكم غير
يعد مرض باركنسون ( )PDثاني أكثر االضطرابات العصبية شيو ً
طبيعي لي بروتين أالفا سينوكلين  α-synucleinهذه التراكمات معروفة باسم Lewy Body
) (LBsو ) ،Lewy neurites (LNsباإلضافة إلى فقدان كبير في الخاليا العصبية الدوبامين
في منطقة  SNpcمن الدماغ .تشير الدالئل الحديثة إلى أن حقن ألياف األلفا سينوكليين ()PFF
في الفئران يؤدي إلى تكوين  LBsو  LNsفي مناطق الدماغ المترابطة تشريحيا ً وبالتالي
يؤدي إلى ظهور المرض بعد عدة أشهر .في هذه الدراسة ،قمنا بتقييم تأثير جرعات مختلفة
مادة  MPTPفي تحفيز انتشار بروتين األلفا سينوكليين عند حقن ألياف األلفا سينوكليين
( .WT α-Syn )PFFلقد وجدنا أن ألياف األلفا سينوكليين في منطقة  striatumفي المخ
قادره على االنتشار إلى  SNpcخالل فترة زمنية قصيرة .ومن المثير لالهتمام ،أن حقن
جرعة منخفضة من 10( MPTPمغ  /كغ) بعد  6أسابيع من حقن ألياف األلفا سينوكليين يزيد
من االنتشار في حين أن جرعة عالية من  25( MPTPمغ  /كغ) تقلل من االنتشار .عززت
الجرعة المنخفضة من MPTPمن التراكم المرضي لـبروتين األلفا سينوكلين المفسفر
( .)pS129كانت غالبية األلفا سينوكلين المتراكمة والتي تم التعرف عليها بواسطة الجسم
المضاد لبروتين األلفا سينوكلين ،مقاومة النزيم  .proteinase kعالوة على ذلك ،وجدنا أن
حقن ألياف األلفا سينوكليين وحده يؤدي إلى فقدان  %12فقط من الخاليا العصبية الدوبامينية
بينما تسبب اضافة الجرعة منخفضة من MPTPإلى فقدان  %33من الخاليا العصبية
الدوبامينية مقارنة بنسبة  %100في الفئران المحقونة بمحلول محلي .مزيج من ألياف األلفا
ً
عجزا في التنسيق الحركي .تجدر
ضا
سينوكليين والجرعة المنخفضة من  MPTPيسبب أي ً
اإلشارة إلى أن جرعة منخفضة من  MPTPوحدها ال تسبب موت نسبه كبيره من خاليا
الدوبامين .ومن المثير لالهتمام ،أن الحيوانات التي حقنت بي ألياف األلفا سينوكليين والجرعة
العالية من  MPTPأظهرت تنشي ً
كبيرا للخاليا الغير عصبيه  Glial cellsمع نقص في
طا
ً
انتشار بروتين األلفا سينوكليين وغالبية األلفا سينوكلين رصدت في النواة.

x

لذلك ،تشير النتائج التي توصلنا إليها إلى أن األلفا سينوكليين مع جرعة منخفضة من MPTP
تزيد من التحويل المرضي وانتشار بروتين األلفا سينوكلين وكذلك موت الخاليا العصبية
خالل فترة زمنية قصيرة جدًا .ويمكن استخدام هذا النموذج لدراسة آلية انتشار بروتين األلفا
سينوكلين والختبار العقاقير المحتملة لـعالج مرض باركنسون.

مفاهيم البحث الرئيسية :مرض باركنسون ،ألفا سينوكليين ،ألياف األلفا سيوكليينMPTP ،
أجسام ليوي.
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Chapter 1: Introduction
1.1 Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative
disorder after Alzheimer's disease. The disease was first described by an English
physician James Parkinson’s in one of his essays, and he described the disease as
“shaking palsy” in 1817. In this essay, he described the case study of six patient who
were suffering from movement disorder (Parkinson, 2002). Famous French
neurologist Jean Martin Charcot further refined the clinical feature of this disease
and named the disease honoring James Parkinson. Pathologically, Parkinson's
disease is characterized by the loss of dopaminergic neurons in SNpc and the
presence of abnormal protein aggregates in the cell body (Lewy body) and the cell
processes (Lewy neurites) (Farrer, 2006).
1.2 Epidemiology

Parkinson's Disease is the most common age-related neurodegenerative
movement disorder. The incidence of PD before the age of 50 is rare, but the risk of
the disease increases in people above 60 years old. The incidence of PD in men is
more than women in a ratio of 3:2, and exposure to pesticides or brain injury are
considered risk factors that can increase the chance of getting the disease. Most of
the PD cases are due to combined action lifestyle, environmental and epigenetic
(sporadic) factor while only 10% of all PD cases are due to a rare mutation in a
single gene segregate with the disease in families (familial) (Lill, 2016). Autosomal
recessive PD (ARPD) is linked to mutations in DJ-1, PARKIN, PINK1 and DNAJC6
gene while Autosomal-dominant PD linked to mutations in SNCA, LRRK2, and
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VPS35 gene. The familial form of the disease is usually characterized by the early
onset of the symptoms (Farrer, 2006; Lill, 2016).
Although the mutation in gene represents up to 10% only of PD cases (Lill,
2016), but studying the mutations in these genes help us to understand the
pathological pathways of the disease.
1.3 Clinical Feature
The symptoms of PD could be divided into motor and non-motor symptoms.
Nonmotor symptoms such as fatigue, sleep disturbance, rapid eye movement,
constipation, loss of smell sense and impairment of the autonomic nervous system
usually start at early stage of the disease up to 20 years before the appearance of first
motor symptom. The premotor phase of the disease is the potential target for treating
the disease by stopping the neuronal loss before it reaches the progression phase,
however, the available treatment is based on replacing the dopamine rather than stop
the loss of the neuron or the progression of the disease. The difficulty of diagnosis
PD in early stage is also an additional challenge in controlling the disease. PD
usually diagnosed with the start of the motor symptoms such as muscle rigidity,
bradykinesia, resting tremor and impairment of postural and gait (Kalia et al., 2015).
These symptoms appear when the loss of the dopaminergic neurons reach 50%-60%
and the loss of dopamine content reach 70%-80% (Schapira, 2008b). The late-stage
complications start when the resistance to the L-dopa start and that usually after 15
year of the disease diagnosis. The late-stage complication include dyskinesia induced
by L-dopa, postural hypotension and increase in falls, urinary incontinence, decline
in cognitive function, dementia, Hallucination and depression (Hely et al, 2005).
End-stage symptoms are linked lower rate of self-independence and as a result
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reduce in quality of life (Trojanowski et al., 2013). Due to the presence of motor and
non-motor symptoms PD is now described as a complex clinicopathological disease
(Kalia et al., 2015).

Figure 1: Clinical feature of PD (Kalia et al., 2015)

1.3.1 Degeneration of the Midbrain Dopaminergic System
Dopamine (DA) neurons in the midbrain playing an important role in
different brain functions including motor performance, reward-based learning,
motivation, working memory, and goal-directed behavior. As a result, many
neurological and psychological disorder emerges from selective distraction of
dopaminergic neurons in the midbrain such as PD and schizophrenia (Dragicevic et
al., 2015).
Dopaminergic neurons in the midbrain are diverse in their gene expression
pattern, electrophysiological property, axonal projection to the cerebral cortex and
striatum. This diversity leads to diversity in response to different stimuli. As a result,
the neuron in this region could be subdivided into at least 5 different neuronal
populations and are anatomically present mainly in two areas which are substantia
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nigra pars compacta (SNpc, area A9) and ventral tegmental area (VTA, area A10).
Each type of this neuron has different neuronal connections throw it’s afferent and
efferent projection which serve for the diversity in response to environmental events.
Neurons that control motor performance and development of habit located mainly in
the ventral tier of the SNpc and innervate mainly the dorsolateral striatum (putamen).
Nonmotor symptoms of PD such as psychological complications and cognitive
dysfunction could be due to the loss of other neurons in VTA and SNpc (Hassan &
Benarroch, 2015). The Dopaminergic neuron of the midbrain could be divided into
subgroup depend on the difference in their relative expression of some marker such
as ion channels and calcium-binding protein Calbindin. For Example, the selective
marker for glutamatergic neuron vesicular glutamate transport-2 is expressed on
some VTA dopaminergic neurons which means that this neuron can use both
dopamine and L-glutamate as a neurotransmitter (Hassan & Benarroch, 2015).
In PD, Dopamine neuron in A9 area that located in SNpc and its projection
innervate the striatum are selectively degenerate in comparison to other midbrain
dopamine neurons. However, at late stage of the disease dopamine neurons in other
areas of midbrain are also affected (Dickson, 2012).
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Figure 2: Main connections of midbrain dopaminergic neurons
(Hassan & Benarroch, 2015)

1.3.2 Neuronal Loss in Other Areas
Although the majority of the studies in PD field focus on studying the dopaminergic
neuron in the SNpc area, number of studies address neuronal loss in other areas such
as, cholinergic neurons in Pedunculopontine Nucleus (PPN), noradrenergic neurons
in Locus Coeruleus (LC) and cholinergic neurons of the Dorsal Motor Nucleus of the
Vagus (DMV). Other areas such as Raphe Nuclei (RN), Ventral Tegmental Area
(VTA), Hypothalamus studies shows neuronal loss with increase severity of the
disease. In areas such as Nucleus Basalis of Meynert (NBM), Olfactory Bulb and
neurons of the enteric nerves system (ENS) no clear evidence of neuronal lose in
these areas (Giguère et al., 2018).
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1.4 Pathological Hallmark of PD
The characteristic pathological hallmark of PD is the loss of dopamine
neurons in SNpc and the presence of abnormal protein aggregate as a major
component of Lewy body and Lewy neurites. Additionally, postmortem PD brain
tissue has been shown to have elevated number of oxidative stress marker in SNpc
neuron such as nucleic acid oxidation marker the 8-hydroxyguanosine (8OHG)
(Zhang et al., 1999) and products of lipid peroxidation including 4-hydroxynonanol
protein adduct and malondialdehyde (Dexter et al., 1989; Yoritaka et al., 1996).
Moreover, it has been reported that the content of polyunsaturated fatty acid in SNpc
is reduced compared with other brain regions (Dexter et al., 1989). There are number
of characteristic features in dopamine neuron in SNpc make them more labile for
oxidative stress and selective degradation in PD (Hassan & Benarroch, 2015). One
of them is that the dopaminergic neurons use dopamine as a major neurotransmitter
which has the ability to autoxidize and generate reactive oxygen species (ROS)
(Zhang et al., 1999). Another reason that SNpc dopaminergic neurons contain low
levels of calbindin, the calcium-binding protein. This make cells vulnerable to
fluctuated calcium level when the calcium homeostasis is impaired. Calcium can
activate the enzyme of the tricarboxylic acid cycle, increase the activity of the
electron transport chain and activate mitochondria nitric oxide synthase which leads
to increase nitric oxide (NO) level leading to generation of ROS and increasing
oxidative stress (Dragicevic et al., 2015).
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Figure 3: The main brain regions affected in PD (Farrer, 2006)

1.5 α-synuclein and PD
α-synuclein is the main component of the intraneuronal spherical
eosinophilic protein aggregate known as Lewy body which considered as one of the
characteristic pathological hallmarks of the sporadic form of PD. α-synuclein in
Lewy body is ubiquitinated (Bisaglia et al., 2008) and phosphorylated at Ser 129
(Anderson et al., 2006). In addition of being the main component of Lewy body,
point mutation or multiplication in the gene that encodes α-synuclein cause dominant
inherited form of Parkinson’s Disease (Conway et al., 1998; Kara et al., 2015). The
above two observations indicate that α-synuclein may play a major role in PD. Gene
duplication or triplication of the SNCA that found in familial inherited form of PD
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indicates that the level intracellular α-synuclein should be kept under control
(Vicario et al., 2018). Failure to keep this cellular homeostasis of α-synuclein by
ethier increase the expression of the protein or failure to degrade it can lead to
accumulation of the protein in the cytosol. The accumulation of α-synuclein in the
cytosol may lead to protein aggregation. The aggregation of α-synuclein is
considered an important pathological marker for PD. Identifying the toxic form of αsynuclein is a contradictory issue as it is not known whether the aggregated mature
fibril or the intermediate oligomer is more toxic. Finding the toxic form of the αsynuclein may help the researchers to target this form in order to inhibit the toxicity
and the spreading of this protien, which may help to stop the propagation of the
disease (Vicario et al., 2018).
1.5.1 α-synuclein Structure
SNCA gene encodes for a small acidic protein called α-synuclein which
belongs to the synuclein family that contains β and γ synuclein. β and γ synuclein
share high homology with α-synuclein gene and protein. All three proteins are highly
expressed in the brain and they have lower expression in other tissue. In addition, it
has been found that γ synuclein is highly expressed in breast cancer (Lavedan, 1998).
α-synuclein protein has molecular weight about 14KDa and contains 140
amino acid and it belongs to intrinsically disorder protein (IDP) family. Proteins in
this family lack of define secondary structure, however, they acquire define structure
when they interact with a specific binding partner. α-synuclein protein has three
domains; the N terminal region from 1 to 60 amino acid which contains 4 imperfect
repeats of 11 amino acid with a conserved sequence of six amino acid KTKEGV.
This is the region where most of the point mutations have been found in PD for
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example A30P, A53T, and E46K. The NAC domain (non-Aβ component of
Alzheimer’s disease amyloid) is the region from 61 to 95 is a highly hydrophobic
region and its responsible for protein aggregation (Gerard et al., 2013). As the
deletion of this region inhibits the formation of α-synuclein filament (Giasson et al.,
2001). Amino acid from 96 to 140 is the C-terminal region which is rich in acidic
amino acid. α-synuclein has a compact structure due to the interaction between the
C-terminal and the NAC region (Gerard et al., 2013). This interaction between the
two regions prevents aggregation of α-synuclein (Bertoncini et al., 2005).
In vitro study revealed that α-synuclein binding to the membrane acquires a
define conformation consists of two antiparallel helices (Val3-Val37) and (Lys45Thr92) connected together with a linker region while the C- terminal tail remain
unstructured (Ulmer et al,. 2005). The same study also suggests that the interaction
of α-synuclein with the membrane cause changes in the conformational structure of
α-synuclein and also changes the stability and the fluidity of the membrane which
may give an indication on α-synuclein physiological function (Ulmer et al., 2005).
As it has been found that the interaction of wild type α-synuclein with the
phospholipid micelles cause flatten in their surface curvature (Auluck et al., 2010).
On the other hand, when α-synuclein aggregated, it acquires an antiparallel β-sheet
structure (Celej et al., 2012). The β-sheet structure of α-synuclein could be detected
throw it’s interaction with the fluorescent dye Thioflavin T (Wördehoff & Hoyer,
2018).
Although this the wildly accepted description of α-synuclein structure, a 58
kDa tetrameric structure has been proposed to be the natural structure of α-synuclein.
This tetrameric structure has the ability to resist α-synuclein aggregation and

10
distribution of this tetramer structure causes aggregation of α-synuclein (Bartels et
al., 2011; Dettmer et al., 2015; Wang et al., 2011). This tetrameric structure does not
induce any toxic effect on the cell or form pore in the cell membrane (Wang et al.,
2011) Point mutation in α-synuclein such as mutation describe in PD patient A53T,
A30P, E46K, G51D and H50Q cause failure in formation of this tetramer structure
(Dettmer et al., 2015; Wang et al., 2011). This data suggests that the monomeric and
the tetrameric structure exists together in equilibrium and when this equilibrium is
disturbed the monomeric structure increases to mediate the pathology (Dettmer et al.,
2015; Wang et al., 2011). This supported by the fact that duplication or triplication
of the SNCA gene causes the synuclein pathology (Wang et al., 2011).

Figure 4: The two antiparallel helix of α-synuclein (Ulmer et al., 2005)

1.5.2 α-synuclein Function
The exact function of α-synuclein is not fully known yet. However, studying
the subcellular localization of α-synuclein shows that it present in the cytosol, Golgi,
ER, mitochondria and nucleus (Kontopoulos et al., 2006; Ling Zhang et al., 2008).
This suggests that it may have a role in mitochondria function or intracellular
trafficking. Although α-synuclein present in most of the cell organelles, the highest
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localization of α-synuclein is observed in the presynaptic nerve terminal of the
neuron (Zhang et al., 2008) suggests that it may play role in regulating the activity of
the synaptic membrane through control the release of the neurotransmitter (Burré &
Südhof et al., 2010).
Studies suggest that the interaction of α-synuclein with other proteins may
give indication of it is role in the cell as α-synuclein interacts with a large number of
proteins (Breydo et al., 2012). Interaction of α-synuclein with SNARE family protein
enlighten the role of α-synuclein in regulating the synaptic function. A study
conducted in 2010, shows that α-synuclein can promotes SNARE-Complex
Assembly. As α-synuclein can bind to the phospholipid membrane through the N
terminal motif and to the synaptobrevin-2 throw the C terminal domain. This study
also found that TKO mice show a decrease in SNARE complex assembly and agedependent neurological dysfunction (Burré et al., 2010). In addition, it has been
found that α-synuclein may positively regulate the final step in exocytosis. The
synaptic vesicle protein, cysteine string protein alpha (CSPα) is an important protein
for neuronal survival. Deletion of the gene encodes for this protein cause deficit in
SNARE complex assembly and neurodegenerative disease. Expression of αsynuclein in mice lacking the CSPα cause recovery in the SNARE complex
assembly and rescue the mice from neurol degradation (Chandra et al., 2005). One
the other hand, another study shows that α-synuclein may negatively regulate the
synaptic vesicle trafficking by inhibiting the release of the vesicle (Larsen et al.,
2006) and stabilize the vesicles by reducing the curvature stress and as a result
inhibit the premature fusion with the target membrane (Perlmutter et al., 2009).

12
It has been found that α-synuclein can interact with tyrosine hydroxylase
(TH) enzyme. α-synuclein shows a regulatory effect in dopamine biosynthesis by
inhibiting the TH activity in the presynaptic neuron (Perez et al., 2002). α-synuclein
regulate TH activity by increasing the concentration of the non-phosphorylated TH
(less active) over the phosphorylated form (more active) (Peng et al., 2005). αsynuclein can also, regulate the concentration of dopamine in the synaptic vesicle by
increase dopamine uptake by binding to the C-terminal of DA transporter (Hara et
al., 2013). It has been reported also that α-synuclein can inhibit the conversion of LDOPA to Dopamine by negatively regulate the activity of aromatic amino acid
decarboxylase (Tehranian et al., 2006).
1.5.3 α-synuclein Proteolysis
It has been suggested that defects in the protein degradation system may play
an important role in PD pathology. Two mains cellular systems which are
responsible for α-synuclein degradation are the lysosome autophagy system (LAS)
and the ubiquitin-proteasome system (UPS). Proteins are more liable to aggregate
when there is an accumulation of oxidized or mutant form of the protein in the
cytoplasm (Xilouri et al., 2013).
The UPS work through two main steps, the first step is the recognition of the
target protein by forming a covalent bond between the ubiquitin and the lysine in the
target protein, then a chain of polyubiquitin is made by adding of ubiquitin to the
protein. Following that the 26s proteasome recognizes the target protein throw the
polyubiquitin chain and digest the protein forming oligopeptides and free ubiquitin
(Xilouri et al., 2013). In the brain of PD patients, it has been found that the
aggregated α-synuclein in Lewy body is ubiquitinated which may suggest that deficit
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in proteolysis and dysfunction of the UPS system may play a role PD pathology
(Mcnaught & Jenner, 2001).
LAS is a vesicle-mediated system that mediates proteins and cellular
organelles degradation. In LAS the degradation takes place inside the lysosome. The
lysosomal lumen is acidic in nature which is important for optimal function of the
degradation enzymes. Degradation enzymes such as nucleases and proteases that
present inside the lysosome responsible for degrading of the targets. The LAS
system can be divided into 3 subtype microautophagy, macroautophagy, and
chaperone-mediated autophagy. The chaperone-mediated autophagy is a highly
specialized system that recognizes a specific pentapeptide sequence in the target
protein. The macroautophagy is characterized by the formation of autophagic
vacuole which can fuse with the lysosome forming autophagolysosome. Number of
studies found that inhibiting the UPS does not induce any accumulation of αsynuclein within the cell which may suggest that the LAS could be the main
degradation system for α-synuclein, not the UPS (Xilouri et al., 2013). It has been
suggested that within the LAS, macroautophagy and chaperone-mediated autophagy
are the main pathways in α-synuclein degradation (Xilouri et al., 2013). Evidence
shows that there is a crosstalk between the two systems, and inhibition of one this
system cause accumulation of α-synuclein (Xilouri et al., 2013).
1.5.4 Phosphorylation of α-synuclein
A number of post-translation modification in α-synuclein are detected in
Lewy body from PD brain tissue such as nitration, ubiquitination, C-terminal
truncation serine and tyrosine phosphorylation (Beyer & Ariza, 2013). One of the
most common post-translation modifications in α-synuclein is the phosphorylation at
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Ser129. The phosphorylation of α-synuclein at the C- terminal region represent 90%
of α-synuclein in Lewy body while in the normal brain the phosphorylation of αsynuclein represents 4% only of total α-synuclein in the brain (Beyer & Ariza,
2013). As other protein, the phosphorylation of α-synuclein is controlled by Kinases
and phosphatase The kinase responsible for α-synuclein phosphorylation is Polo-like
kinase PLK2 and PLK3, G protein-coupled receptor kinase GRK2, GRK3, GRK5
and GRK6 and casein kinase CK1 and CK2 (Beyer & Ariza, 2013). While the
responsible for dephosphorylation of α-synuclein is the Phosphoprotein phosphatase
2A (PPA2) (Cavallarin et al., 2010).
Although the exact role of the phosphorylation at Ser129 in α-synuclein
aggregation and PD pathology is still not clear. The phosphorylation of α-synuclein
in Lewy body and the limited phosphorylation in the normal brain suggest that the
prosses of phosphorylation at this site is strictly controlled in the normal brain. That
highlights the role of α-synuclein phosphorylation in PD. Indeed a recent study
shows that phosphorylation of exogenous α-synuclein fibril injected in the striatum
could spread in the brain and mediate the pathological effect of α-synuclein and
initiate the loss of dopaminergic neuron in the SNpc (Karampetsou et al., 2017).
Some studies show that phosphorylation at Ser129 inhibits fibril formation in vitro
(Paleologou et al., 2008). However, another study claim that the phosphorylation at
Ser129 does not play any role in regulation of α-synuclein aggregation (Waxman &
Giasson, 2011). This may indicate that the phosphorylation at this site may happen
during the development of the mature fibril or after LB formation (Beyer & Ariza,
2013).
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By studying the relation between the α-synuclein phosphorylation and
solubility during the progression of PD using postmortem sample, it has been found
that the phosphorylation at Ser129 and α-synuclein aggregation increase during the
late stage of the disease and its accompanied by changing the cellular localization of
α-synuclein throw increase ratio of membrane-bound α-synuclein over the cytosolic
α-synuclein, which suggest that phosphorylation of α-synuclein is important for
membrane binding (Zhou et al., 2011). Another study found that α-synuclein
undergoes dephosphorylation when it is dissociated from the membrane which
suggests that the phosphorylation of Ser129 may play a role in regulation the αsynuclein binding to the membrane (Visanji et al., 2011).
1.5.5 α-synuclein Spreading
Discovering that the α-synuclein has the ability to propagate from neuron to
neuron raises the importance of α-synuclein in the progression of PD. The ability of
α-synuclein to spread was first reported in embryonic dopaminergic neuron grafted
in the striatal of a PD patient. The healthy grafted embryonic neuron in postmortem
examination shows accumulation of α-synuclein or Lewy body similar to that one
found in the patient neuron (Kordower et al., 2008; Li et al., 2008) this accumulation
was time-dependent (Astradsson et al., 2008). This phenomenon was confirmed by
studying the behavior of α-synuclein in animal models and cell lines (Hansen et al.,
2011; Hiltpold et al., 2009). From this observation, the prion-like hypothesis of αsynuclein was established. This hypothesis proposed that when α-synuclein
aggregate in the neuron they acquire feature that allow them to travel through the
neuronal axonal to other brain region and through the nerve terminal the α-synuclein
released into the extracellular space. This aggregated protein that released from the
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neuron can be up-taken by other neuron and act as a seed that initiates the
aggregation of endogenous α-synuclein (Angot et al., 2010). It has been suggested
that conditions such as oxidative stress and impairment of proteolytic prosses could
increase the spreading of α-synuclein (Tyson et al., 2016). However, in human, the
prion hypothesis dose not explain why some areas with high connectivity to SNpc
such as striatum and globus pallidus externa do not show Lewy body (Surmeier et
al., 2017). In animal model unilateral injection of preformed fibril of α-synuclein
(PFFs) in the striatum of wild type mice shows spreading of α-synuclein in area of
brain that it is directly connected with the striatum and led to dopamine neuron loss
in SNpc and deficit in motor coordination of the mice within 180 days (Luk et al.,
2012). Braak et al. describe the sequence of propagation of α-synuclein in PD. He
describes an ascending pattern of propagation that can be divided into stages in
which stage 1 and 2 of the propagation start in the brainstem and olfactory bulb then
reaching the substantia negra and amygdala in stage 3 and 4. In the final stage (stage
5) the α-synuclein spread through the neocortex (Braak et al., 2003). Interestingly αsynuclein was detected in the enteric nervous system (ENS) during the early stage of
PD (Braak et al., 2006). However, studying the clinical symptoms and the Braak’s
pathological stage in people with PD shows that only half of brain samples show
spreading of Lewy body following the Braak model (Surmeier et al., 2017). A
recent study found that inclusion of α-synuclein can propagate from the stomach
wall through the vagus nerve to the dorsal motor nucleus in the brain (Uemura et al.,
2018). However, it’s still not clear whether α-synuclein travels from the brain to the
gastroenteric system or it is travel in a retrograde manner via the vagus nerve to the
brain.
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1.6 Possible Pathological Pathway of PD
1.6.1 Oxidative Stress
One of the major players in the pathology of PD and neurodegenerative
disease, in general, is the oxidative stress. ROS are normally produced by the living
cells and their level is kept under check by the antioxidant system. However, when
the level of production ROS exceeds the level of antioxidant enzyme in the cell the
oxidative stress occurs (Haan et al., 2004; Nagy, 2013; Oelze et al., 2013). Increase
production of ROS led to damage of intracellular components such as lipid, protein,
and DNA (Liu et al, 2017). Several study found that in PD patient brain there is
reduction in the content of the polyunsaturated fatty acid in SNpc (Dexter et al.,
1989) and elevation of several oxidative stress marker such as 4-hydroxynonanol
protein adduct and malondialdehyde as marker for lipid oxidation and elevation in
8-hydroxyguanosine (8OHG) as a marker for nucleic acid oxidation (Dexter et al.,
1989; Yoritaka et al., 1996; Zhang et al., 1999). The main sources of oxidative
stress in the dopaminergic neurons are mitochondrial dysfunction, dopamine
metabolism, and chronic neuroinflammation.
1.6.2 Mitochondrial Disfunction
ROS formation is increased in the case of mitochondrial dysfunction.
Mitochondria provide energy to the cell by oxidative phosphorylation. This process
is the main source of ROS which produced as a byproduct. There are many evidence
support the mitochondrial dysfunction theory in PD. first, It has been found that
patient with PD has reduced level of complex I of the mitochondria respiratory chain
complex in the SNpc, platelets and skeletal muscle (Schapira, 2008a). Secondly, in
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the familial form of PD where a rare mutation in one of the genes can cause PD.
Genes such as PARKIN, DJ1, and PINK1 are suggested to regulate the mitochondrial
function. Mutations in these genes are related with increase in oxidative stress and
represent the base of the early-onset form of PD (Schapira, 2008a). Adding to that
mitochondrial toxin such as MPTP and rotenone which inhibit complex I are able to
produce

Parkinson like symptoms (Schapira, 2008a). MPTP, the chemical

compound that when injected throw a peripheral route it can cross the blood-brain
barrier. In the brain MPTP metabolite to MPP+ which is selectively uptake by
dopaminergic neuron and accumulate in the mitochondria. In the mitochondria,
MPP+ inhibits complex I of the electron transport chain which suppress the ATP
production and increase the production of ROS (Langston, 2017).
DJ-1 is an oxidative stress sensor that translocates under condition of
oxidative stress to the mitochondria matrix and intermembrane space (Wilson et al.,
2004; Zhang et al., 2005). In the mitochondria, DJ-1 protein interacts with the
subunit of complex I of the mitochondria ETC and regulates its activity (Hayashi et
al., 2009). DJ-1 has a neuroprotective effect against cell death induced by oxidative
stress (Junn et al., 2009). Mutation in DJ-1 that causes loss of function is founded in
the inherited form of the PD patient. Patients with the DJ-1 mutation are experienced
an early onset of PD symptoms usually between the 20s - 30s years old. DJ-1 has
been identified in PARK7 loci (Houlden & Singleton, 2012). DJ-1 KO mice show
altered mitochondria morphology, reduce in membrane potential, increase in ROS
production and loss of nigrostriatal DA neuron (Goldberg et al., 2005; Irrcher et al.,
2010).
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Completely loss of function of PINK1 and PARKIN leads to selective loss of
DA neurons, bradykinesia, rigidity, and tremor in PD patients. PD patients with
PINK1 and PARKIN mutations are characterized by a slow progression of the
disease and good response to levodopa treatment (Klein et al., 2006; Puschmann,
2013; Thompson et al., 2013).
Mutations in the PTEN induced putative kinase1 (PINK1) gene is the second
most common causative gene of recessive PD. The first mutation was originally
discovered in 2004 in three families with recessively inherited PD. PINK1 mutation
liked to early-onset PD, but also it has been found that mutation in PINK1 can be
linked also with late-onset PD (Klein et al., 2006; Valente et al., 2004). PINK1
encodes a 581-amino-acid protein with an N-terminal mitochondrial targeting
sequence, a C-terminal regulatory domain, and a conserved serine/threonine kinase
domain. Mutation in PINK1 has been linked to the early onset of PD (Trempe &
Fon, 2013). One of the important roles of PINK1 is its neuroprotection activity as
downregulation of PINK1 increases the neuron sensitivity to the neurotoxin and
expression of wild PINK1 protects the dopaminergic neuron from the effect of the
neurotoxin (Haque et al., 2008). Interestingly a study found that induce a mutation in
the PINK1 kinase domain similar to that associated with PD disrupts the
neuroprotective function of PINK1 which suggests that the cytoplasmic action of this
kinase domain is important for the neuroprotection activity (Petit et al., 2005). Also,
it has been found that overstimulation of PINK1 protects cells against apoptosis
while siRNA mediated depletion of PINK1 increase vulnerability to apoptotic cell
death but the mechanism by which PINK1 protects the cell against apoptosis is not
fully understood (Deng et al., 2005; Petit et al., 2005). Mutations in PINK1 cause
mitochondrial morphological abnormality by unknown mechanisms and loss of
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membrane potential which led to disrupting the mitochondrial function. Also, it has
been found that morphological deficit could be ameliorated by increasing the
expression of parkin wild-type in human cell line (Exner et al., 2007).
PARKIN gene mutation is the second most frequent form of Familial PD and
the majority of ARPD are related to mutations in PARKIN. Indeed 50% of autosomal
recessive juvenile PD (ARJPD) patients after the age of 25 years are carrying a
mutation in PARKIN. PARKIN plays an important role in mitochondria homeostasis
by different pathways and it’s directly linked to PINK1 gene. It’s also may involve in
oxidative stress response and cell death pathways (Hattori & Mizuno, 2017).
Some studies suggest that PD related to PINK1 or PARKIN mutation have
different pathological mechanism due to the absence of Lewy bodies. However,
some study had successfully shown the presence of Lewy bodies in PD case with
mutations in PINK1 and PARKIN and they link the variability in ability to detect
Lewy body in patient with PINK1 or PARKIN mutation with the age of the patient
when they develop the disease (Cornejo-Olivas et al., 2015; Farrer et al., 2001).
1.6.3 Neuroinflammation
Neuroinflammation plays an important role in PD. However, it is not known
whether the neuroinflammation is a consequence of neuron degradation or it is the
underlining cause of neurodegeneration in PD. The process of inflammation in the
brain is contributed mainly to the resident brain immune cell microglia and astrocyte
and other cells from the peripheral immune system that can infiltrate to the brain
during inflammation (Doty et al., 2015). In PD which is an age-related disease the
possibility of inflammation increase as the chronic inflammation increases with age
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(Franceschi et al., 2000) Some study suggest that the peripheral inflammation may
stimulate the development of neurodegradation (Perry, 2004). It has been suggested
that inflammation in the peripheral immune system can trigger inflammation
response in the CNS and produce regional neuroinflammation in the brain which
may lead to neurodegeneration (Cunningham & Holmes, 2007).
The proinflammatory cytokines that produced due to activation of the
immune system can penetrate BBB (Hoogland et al., 2015) . That introduced the
idea that the status of the peripheral immune system could be considered as a tool in
clinical diagnosis of PD. On the other way, it has been found that In PD, there is a
significant increase in the level of α-synuclein in the blood which can cause
inflammation in the peripheral immune system which leads to idea that
neurodegradation in PD may influence the inflammation response in the peripheral
immune system (Theodore et al., 2008). In PD patient brain sample it has been found
that there is activation of microglia that expressing the major histocompatibility
complex class II (MHC-II) which suggest that the microglia may play role in the
pro-inflammatory process (Rocha et al, 2015). All this finding together highlights
the important role of inflammation in PD.
1.6.3.1 Oxidative stress due to neuroinflammation
Oxidative stress occurs when the rate of formation of ROS exceeds the
capacity of the antioxidant system in the cell to detoxify them. Microglia activation
leads to increase the proinflammatory cytokine levels such as (TNFα, IL-1β, and IL6) and trigger the production of ROS (Collins et al., 2012) and that led to more
inflammation and neurodegradation , and this situation could be described as a
vicious circle.

22
In PD patient it has been found that there is a change in the biochemical and
immunological profile of the patient (De Farias et al., 2016). Also, it has been found
that there is a disturbance in the balance between the production of ROS and the
antioxidant system. It has been found that there is increase in ROS production and
oxidative damage which increases with the progression of the disease. The oxidative
stress marker can be detected in serum and in the peripheral immune cells of the
patient as the peripheral blood mononuclear cells (PBMC), elevation of DNA
damage marker the 8-hydroxydeoxyguanosine (8-OHdG) in leukocytes and
elevation of lipid peroxidation marker malondialdehyde (MDA) in blood plasma
(Chen et al., 2009; Prigione et al., 2009).
ROS can be generated also from neutrophils at the infection site. That’s why
neutrophils consider as an important source of ROS and may be an important player
in PD. It has been found in patients with PD that the activity of NO-synthase in
neutrophils of peripheral blood is elevated, which causes an increase in the
production of nitrogen monoxide (NO) and reduction in the activity of catalase
enzyme which is an antioxidant enzyme (Barthwal et al., 1999). In addition to that,
the phagocytic property of the neutrophils is decreased in PD patients (Salman et al.,
1999). Some studies suggest that the activation of enzymes such as NADPH oxidase
(NOX2) in microglia can increase the production of ROS that can diffuse outside the
microglia and cause neurotoxic damage to the neighboring neuron. Adding to that
the activation of NADPH oxidase could initiate a redox signal that may act as an
amplifier for the inflammatory response. As redox signal increase sensitivity of the
microglia to pro-inflammatory stimuli and enhance the production of neurotoxin
cytokine which may lead to chronic microglial activation (Surace & Block, 2012).
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Environmental toxin and endogenous protein can activate the microglia cells
the resident immune cell in the brain. Activated microglia are considered an
important source for ROS (Block et al., 2007). In PD patients, it has found that
microglial is activated in the SNpc and in the olfactory bulb (Doorn et al., 2014a;
Doorn et al., 2014b). In animal model of PD microglial activation are present in
striatum and SNpc (Lawson et al., 1990; Stott & Barker, 2014) and it has been
found that degradation of the of dopamine neuron in PD is correlated with the
chronic neuroinﬂammation and it seems that the microglia is the main player in this
prosses with respect to astrocyte and oligodendrocytes (Perry, 2012).
1.6.3.2 Microglia
Microglia can be classified into phagocytic (ameboid), activated and ramified
(resting) microglia. The increase in number, cell volume, and cluster formation are
the characteristics feature for activated microglia. Ionized calcium-binding adapter
molecule 1 (Iba1) is an important marker for microglia. Iba1 is expressed in ramified
and activated microglia and it has a pattern of distribution in the processes and the
cytoplasm of microglia (Sasaki, 2016). Microglia has a similar function and
appearance to macrophages. However, the term amoeboid microglia are used to
highlight that microglia may have a different origin. Some studies suggest that
microglia are derived from pre-existing microglia not from circulating monocytes
(Boche et al., 2013).
Microglia are constantly monitoring the brain microenvironment and when
inflection or tissue damage is detected it acts as first-line defense. Microglia has a
phagocytic property that can remove local debris. It has also, a role in regulating the
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synapse by remove the excess synapse during the development and monitor the
synapse integrity in adults (Perry, 2012).
1.6.3.4 Astrocytes
Astrocytes are another type of immune cell in the brain that expresses GFAP.
Although GFAP is the most common marker for astrocyte, the exact function of
GFAP is still unknown. Some studies show that astrocytes express GFAP to define
the shape of the cell and provide mechanical strength to the cell. Recent studies
show that astrocyte may have other fundamental roles such as, protecting the neuron
against excess neurotransmitter, regulate the neuronal activity, enhance synaptic
plasticity and play a role in regulating the blood brain barrier (BBB). In PD patients,
the number of GFAP positive cells increased with the severity of Dopaminergic
neuron loss in SNpc and it has been found that the GFAP level is increased in the
hypothalamus area (Middeldorp & Hol, 2011).

Figure 5: Activated astrocyte and microglia (Siew & Chern, 2018)
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1.6.4 Dopamine Metabolism
Dopamine is a neurotransmitter that synthesized in the dopaminergic neuron
from the aromatic amino acid tyrosine. Tyrosine is hydroxylated by tyrosine
hydroxylase (TH) which is the rate limiting enzyme in dopamine synthesis which
converts tyrosine to L-Dopa. L-Dopa is decarboxylated by dopa decarboxylase to
form dopamine and after dopamine preform it effect, DA is uptake from the synaptic
cleft by the presynaptic transporter dopamine transporter (DAT) and packaged into
vesicle by

the vesicular monoamine transporter 2 (VMAT2) or degraded by

monoamine oxidase (MAO) (Qi et al., 2012). If dopamine remains in the cytosol due
to failure in storing the dopamine into vesicles or metabolizing it by MAO,
Dopamine in the cytosol may produce reactive quinones, semiquinones, and ROS by
autooxidation or by oxidation reaction catalyzed by metals such as zinc, copper, and
iron (Zucca et al., 2014). Many studies suggest that the selective damage and
degradation of the DA neuron in PD is due to the oxidative stress generated by
metabolism of the dopamine. Dopamine quinones the oxidation product of dopamine
cause oxidative damage to the cellular components which cause cellular dysfunction
that lead to cell death (Zucca et al., 2014). A recent study shows that the
mitochondrial oxidative stress responsible for producing the oxidized form of the
dopamine in the dopaminergic neuron which leads to initiate a toxic cascade that
leads to accumulation of α-synuclein and degradation of dopaminergic neuron in PD
(Burbulla et al., 2017). Adding to that, a study found that mice with reduced
expression of VMAT2 show a change in dopamine homeostasis which mediate
nigrostriatal dopaminergic degradation (Caudle et al., 2007). Also, the VMAT2 mice
knockout model showed an increased sensitivity toward MPTP intoxication
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(Takahashi et al., 1997). This suggest that defect in VMAT2 could be the underlying
cause that leads to degradtion of the dopaminergic neurons in PD (Pifl et al., 2014).
1.7 Animal Model of PD
One of the biggest challenges in PD research is the lack of suitable animal
models that reproduce all the pathological features seen in humans. Researchers have
developed different animal model systems to study the mechanism of the disease as
well as their use in drug discovery. Below we will review some of the available
animal models with enlightening the advantage and disadvantages of these models.
1.7.1 Neurotoxic Model
1.7.1.1 MPTP
In 1982 MPTP was first identified to cause Parkinson's symptoms among the
drug abusers who consume meperidine analog MPTP as a major byproduct of
MPPP. Since then MPTP was excessively used by the PD researchers. MPTP is a
synthetic chemical that was synthesized as a by-product of MPPP. MPTP is
considered one of the most useful neurotoxins that causes neurodegeneration of
Dopamine neurons in SNpc of C57BL6 mouse and produces clinical features of PD
in monkeys. MPTP is a lipophilic compound that can easily cross the blood brain
barrier (BBB) where it is converted to its active metabolite, MPP+ by the glial cells.
It has been reported that MAO B is the enzyme responsible for metabolizing the
MPTP to MPP+. MPP+ is then selectively uptake by the dopamine transporter
(DAT) of the dopaminergic neurons of the SNpc area. It is noteworthy to mention
that the chemical structure of MPP+ is a very similar chemical structure another
neurotoxin, paraquat.
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In the Dopamine neuron, MPP+ inhibits complex I of the mitochondria
electron transport chain causing a decrease in ATP production level and
consequently increases ROS production. It has been found that MPTP can also
damage the vesicular monoamine transporter type 2, which may cause depletion in
dopamine storage and increase the cytosolic dopamine which ultimately
autooxidiezed to dopamine quinone and produce ROS (Langston, 2017).
MPTP has become the tool of choice in studying PD (Tieu, 2011) as it can be
used in different type of toxic doses (Jackson-Lewis & Przedborski, 2007) and it
causes similar pattern of cell loss that observed in PD patient with greater loss of
dopamine neuron in SNpc compared with the VTA dopaminergic neuron (Muthane
et al., 1994). Although the tremendous role of MPTP in the PD research field, some
animal species such as Rats show resistance to MPTP toxicity. However, among
rodent mice shows a high sensitivity to different dose of MPTP (Langston, 2017).
One of the major drawbacks of the MPTP animal model is the lack of Lewy body
formation (Dawson et al., 2005) in rodents. Although within the primates, monkeys,
shows LB when exposed to a low dose of MPTP (Kowall et al., 2000). Many studies
have been carried out using MPTP to examine the regulation and aggregation of αsynuclein to establish relation between MPTP toxicity and α-synuclein (Purisai et al.,
2005) Interestingly, it was shown that α-synuclein null mice are resistance to MPTP
toxicity (Dauer et al., 2002). Recently, it has been shown that silencing of αsynuclein in mice provided neuro-protection against MPTP (Javed et al., 2016).
Moreover, mice with ectopic expression of α-synuclein are sensitive to MPTP
(Fountaine & Wade-Martins, 2007). This could be explained by the decreased
expression of DAT in α-synuclein knockout mice (Chadchankar et al., 2011).
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1.7.1.2 Rotenone
The epidemiological study suggests that exposure to pesticide such as
rotenone is correlated with the incidence of PD (Farrer, 2006). Rotenone is a
naturally occurring widely used pesticide extracted from certain plant species
(Betarbet et al., 2000). Rodents treated with rotenone used as a model for PD as
rotenone can cause degradation of the dopaminergic neurons. Rotenone is a highly
hydrophobic compound that can cross any biological membranes including blood
brain barrier. Unlike MPTP, Rotenone does not need dopamine transporter to be
accumulated in the dopamine neurons (Betarbet et al., 2000). In fact, rotenone could
produce a widespread inhibition of complex I in the electron transport chain in the
brain which causes generation of ROS, and oxidative stress that damages protein and
DNA and induces apoptotic cell death. Rat chronically expose with rotenone shows a
selective degradation of dopamine neurons, sever destruction of nigrostriatal
pathway and intraneuronal cytoplasmic accumulation of α-synuclein fibrils which
look similar to Lewy body that observed in human PD patient (Betarbet et al., 2000).
Rotenone exposed rat has been documented with deficit in motor coordination
similar to PD in humans such as hypokinesia, rigidity, and shaking of the forelimbs
(Betarbet et al., 2000). However, the inconsistent of the result and the low survival
rate of rotenone treated animals is the major limitation of this model (Fleming et al.,
2004). As the uptake of Rotenone into the dopaminergic neuron is independent on
dopamine transporter rotenone shows a systematic inhibition of complex I in the
mitochondria respiratory chain complex.
1.7.1.3 6-hydroxydopamine (6-OHDA)
The first animal model of PD that showed dopaminergic neuron death in
SNpc was the neurotoxin, 6-OHDA (Ungerstedt, 1968). Unlike other neurotoxin
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mentioned earlier, 6-OHDA is produced endogenously (Kostrzewa & Jacobowitz,
1974) and can be up-taken by Dopaminergic and noradrenergic transporter which
give relative selectivity to monoaminergic neuron (Luthman et al., 1989). The
dopaminergic neuron that located in the SNpc is the most affected neuron between
the midbrain dopaminergic neuron by the toxicity of 6-OHDA. 6-OHDA produces
ROS when it accumulates in the cytoplasm of the neuron and produces quinones that
mediate the toxic effect. The major drawback of this model is that 6-OHDA can’t
cross the blood brain barrier so it should be injected locally by stereotaxic in the
SNpc or in the striatum. When 6-OHDA is injected in the SN dopamine neuron
rapidly dies within 24 hours. The stereotaxic injection of 6-OHDA produces a
unilateral loss of neurons while the neurons in the contralateral side could be used as
a control. Due to the unilateral loss of dopamine neuron animal produce
asymmetrical circling behavior. Another drawback of this model is the absence of
interneuronal aggregation (Tieu, 2011).
1.7.2 Genetic Model
The recent discovery of genes mutations in familial PD has provided an
opportunity to develop animal models. Genetic models of PD are mainly focused to
understand the physiological function and the biochemical pathway associated with
mutated genes. Mutations in genes associated with PD have been shown to perturb
number of cellular and molecular pathways such as altering the process that controls
mitochondria quality such as mitophagy and mitochondria fission/fusion which may
cause mitochondrial dysfunction (Exner et al., 2012; Lachenmayer & Yue, 2012;
Morais et al., 2014) lack of protein degradation (α-synuclein), ubiquitin-proteasome
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system (Dantuma & Bott, 2014), increase production of ROS (Joselin et al., 2012)
and alter calcium homeostasis (Gandhi et al., 2009).
Most studies found that there is no significant loss of dopaminergic neurons
in the genetic animal models (Andres-Mateos et al., 2007; Palacino et al., 2004;
Sanchez et al., 2014). These mean to produce the characteristic neurodegeneration of
PD mutation should be induced in more than one gene. Adding to that silencing of
multiple PD genes in mice does not induce significant loss of dopaminergic neuron
in SNpc during animal lifespan as knocking out PINK1, PARKIN and DJ1 in Triple
Knockout mice (TKO) doesn’t produce significant lose in dopamine neuron in the
nigrostriatal pathway neither cause any change in the level of the dopamine
neurotransmitter (Hennis et al., 2013; Kitada et al., 2009).
It has been found also that the deletion of Atg7 the important gene for
autophagy may cause degradation of the dopaminergic neurons in the SNpc. In
mouse model, cell-specific deletion of Atg7 gene in the dopamine neuron in the
midbrain cause neuronal degradation and locomotor deficit (Friedman et al., 2012).
1.7.2.1 α-synuclein (SNCA)
Mutations in SNCA cause autosomal dominant form of PD. Moreover, SNCA
gene duplication and triplication have reported among some patients which suggest
that higher amount of this gene is toxic to the cell. Since mutation in the SNCA gene
was the first mutation identified in the familial form of PD, different mice models
that are overexpressing α-synuclein were developed. However, the major drawback
of these models is the failure to obtain significant degradation of dopamine neuron in
the SNpc area. Two major methods were used to generate α-synuclein transgenic
mouse, selective expression of α-synuclein in the catecholamine neuron by
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expressing α-synuclein under the TH promoter and overexpressing of α-synuclein
using viral vector (Chesselet, 2008).
1.7.2.2 PINK1
PINK1 transgenic animal model doesn’t show significant deficits as they
show a slight age-dependent loss of DA neurons and, they do not show formation of
LB. However, PINK1 KO mice show a mild deficit in mitochondria and have a
higher sensitivity to oxidative stress and ROS production (Haque et al., 2012;
Sanchez et al., 2014). In addition, overexpressing of α-synuclein in PINK1 KO mice
cause significant degradation of DA neuron in SNpc area and increase the level of
phosphorylated α-synuclein (Oliveras-Salvá et al., 2013).
1.7.2.3 PARKIN
PARKIN KO mice can be produced by deletion of exon 2, 3 or 7 in the
PARKIN gene (Goldberg et al., 2003; Perez & Palmiter, 2005; Coelln et al., 2004).
PARKIN transgenic animal model doesn’t show degradation of SNpc dopamine
neuron or behavior abnormalities. PARKIN KO mice show increased susceptibility
to the neurotoxin and inflammatory stimuli (Palacino et al., 2004). Adding to that,
PARKIN KO mice show reduction in the level of norepinephrine in the olfactory
bulb (Goldberg et al., 2003; Coelln et al., 2004).
1.7.2.4 DJ-1
DJ-1 KO mice can be produced by adding a stop codon in exon 1 or by
deletion of exon 2 in the DJ-1 gene. The transgenic animal models of DJ-1 are not
showing major neuronal abnormalities or loss of SNpc neurons, but they are
sensitive to toxins and oxidative stress (Andres-Mateos et al., 2007; Goldberg et al.,
2005). Some DJ-1 KO mice show loss of VTA area DA neurons (Floss et al., 2010).
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1.7.3 α-synuclein PFF Model
This model was first introduced in 2012. Following the intrastriatal injection
of α-synuclein PFF can produce α-synuclein aggregation and propagation to the
SNpc which lead to loss of DA neuron up to 35% within 180 days in SNpc, not the
VTA. This loss in Dopamine neurons is accompanied by motor deficit and reduction
in Dopamine level in the SNpc (Luk et al., 2012). It based on the idea that the
pathological form of α-synuclein has the ability to propagate throw anatomically
interconnected regions. By injecting a synthetic α-synuclein PFF in the striatum will
act as a seed that recruits the endogenous α-synuclein to accumulate and propagate
(Luk et al., 2012). However, injecting soluble monomer form α-synuclein doesn’t
produce aggregation of α-synuclein which may indicate that the α-synuclein fibril
may has a prion like property (Luk et al., 2012; Masuda-Suzukake et al., 2013).
Adding to this that α-synuclein knockout mice fail to produce α-synuclein
aggregation and propagation after intrastriatal injection of α-synuclein seed which
proves that the endogenous α-synuclein are important for spreading of α-synuclein
(Luk et al., 2012).
Creating an animal model that fulfills all feature of the disease in human
would be more reliable in studying the disease and screen for new medication that
can stop or reverse the progression of the disease. Neurotoxic models that show
significant degradation in nigrostriatal dopaminergic neurons and showing
significant motor deficits have a large contribution in our knowledge about the
disease, however, the absence of Lewy body formation and the lack slow
progression of the disease is the major drawback of the neurotoxin model. On the
other hand, transgenic animal model provides a way to study the possible pathway of
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the disease. However, the failure to obtain a consistent neuronal lose is consider the
major drawback of these models.
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Chapter 2: Methods
2.1 Animals
Male C57BL/6 mice (n = 6) were obtained from the United Arab Emirates
University Animal House. At the onset of the experiment, 2-3-month-old mice were
weighed, and the weight was approximately 25-30 grams. Mice were housed in a 12hour light/dark cycle and had access to food and water for the duration of the study.
All experimental procedures were conducted in accordance with the approval of the
UAEU Animal Ethics committee guidelines.
2.2 Stereotaxic Injections
α-synuclein preformed fibril was stereotaxically injected into the striatum
(coordinates from bregma: anterior-posterior, +0.5 mm; medial-lateral, -2.2 mm;
dorsal-ventral, -3.4 mm) (Paxinos & Franklin, 2004) at an infusion rate of 0.5 μl/
minute using a syringe pump (World Precision Instruments, USA). Five
micrograms of wild type recombinant human α-synuclein PFF contain in 2.5ul
PBS or an equal volume of PBS was injected at a constant rate over 5 minutes
followed by one minute interval to allow the seed diffuse properly.
2.3 MPTP Administration
Mice were challenged with two different doses of MPTP or an equal volume
of saline as control once daily for five consecutive days through intraperitoneal
injection [10 mg/kg body weight (b. wt.) or 25 mg/kg b. wt. measured as a free base;
MPTP-HCL; Sigma-Aldrich]. MPTP was first dissolved in normal saline to obtain
12 mg/kg b. wt. or 30 mg/kg b. wt. concentration for injection (Haque et al., 2012;
Lee et al., 2017). MPTP dose was started 6-weeks after the innoculation of α-
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synuclein PFF. Assessment of dopamine producing neurons survival was carried out
2 weeks after the start of the MPTP dosing.
2.4 Brain Collection
At the end of the experiments, the animals were anaesthetized, and cardiac
perfusion was performed using normal saline to wash out the blood followed by 4%
PFA in PBS. The brains were quickly removed and placed in a container containing
4% PFA for overnight incubation at 4°C. PFA solution was exchanged with 10%
sucrose in 0.1 M PB, 0.02% sodium azide twice per day for 2 days. The brains were
then frozen and stored at -80°C for future use.
2.5 Behavior Study
2.5.1 Rotarod
Mice were pretrained to obtain stable performance on an automated four lane
rotarod unit (Rotamex-5, Columbus Instruments, Columbus, OH; lane width, 95 mm,
rod diameter 30 mm). We have used accelerated speed protocol where mice were
pretrained to an increasing speed from 1 to 40 rpm over a period of 5 minutes. On
day one of the training, mice were experienced on accelerated speed from 2 rpm to
20 rpm over 5 minutes. On day two, mice were trained on accelerated speed from 3
rpm to 30 rpm over 5 minutes. On day three, mice were trained on accelerated speed
from 4 rpm to 40 rpm over 5 minutes. At the end of the training period, each animal
underwent four trials with a minimum of 15 minutes interval between trials and the
average of best three runs were recorded as their performance. The trials were
recorded one day prior and one week after the MPTP challenge. Mice were placed
on an accelerating, 3-cm-diameter rotating spindle for testing. The rotarod started at
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4 rpm and increased to 40 rpm over a 5 minutes period. The mean latency to fall
over the three trials was recorded and used for data analysis (Chen et al., 2016).

2.5.2 Grip Test
Grip test was performed one day before initiation of MPTP treatment and one
week after the MPTP exposure. Forelimb Grip strength was measured using
apparatus obtained from Ugo Basile, Comerio, Italy. Mice were held by the tail
above the base plate of the apparatus then lowered toward the apparatus until the
mice grasped a triangle bar. Then mice were gently pulled away along the horizontal
axis and the maximal grip force achieved was recorded. The procedure was repeated
five times for each animal and the mean of the middle three scores was used in the
analysis (Corbo et al., 2002).
2.6 Immunohistochemical Analysis of Brain Samples
For assessment of dopaminergic neuronal death in the SNpc area, brain was
sectioned with the thickness of section 40 µm caudal to rostral covering the whole
SNpc area. Analysis of dopamine transporter integrity was performed using striatal
section of 40 µm thickness. Sections were stained with Tyrosine Hydroxylase (TH)
and Dopamine transporter (DAT) antibodies for SNpc and striatum section
respectively.
2.6.1 Tyrosine Hydroxylase Immunostaining of SNpc Neurons
Every sixth section containing seven coronal serial section rostral to caudal
covering the area from -2.18 to -3.80 mm of bregma from each brain were used for
immunostaining using free floating technique. Sections were washed 3 times for10
minutes each time with 0.01 M phosphate buffered saline (PBS), pH 7.4. Then
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incubated with 10% normal goat serum in PBS 0.3% Triton-X 100 as a blocking
reagent for 1 hour at room temperature. The sections were then washed once with
0.01 M PBS and incubated with primary antibody against TH (TH, immunostar,
1:1000) for 48 hour at 4°C. Biotin streptavidin Donkey anti-mouse antibody was
used as secondary antibody to increase sensitivity (Biotin-sp-conjugated, Jackson
Immuno Research, 1:1000). After washing with PBS, the brain sections were
incubated with streptavidin conjugated with horseradish peroxidase (Sigma,
Streptavidin-HRP Conjugate, 1:200). The immunoreactivity was visualized using
3,3'-Diaminobenzidine (DAB) reaction. After immunoblotting, sections were
mounted and defatted. Number of Dopaminergic neurons was estimated using
stereological Technique.
2.6.2 Dopamine Transporter Staining for Striatum
Sections from the striatum region were collected and the sections were
washed 3 times for 10 minutes with 0.01 M phosphate buffered saline (PBS), pH 7.4.
Then the sections were incubated with 10% normal goat serum in PBS 0.3% TritonX 100 as a blocking reagent for 1 hour at room temperature. Following that, the
sections were washed once with 0.01 M PBS and incubated with polyclonal rat
antibody against DAT (1:1000) for 48 hours at 4°C. DAT is a membrane protein that
is responsible for reuptake the dopamine from the synaptic cleft. Then incubated
with the corresponding secondary antibody and visualized using the avidin-biotin
complex peroxidase reaction of DAB as describe previously. To assess the loss of
striatal fibers in the striatum optical density of the dopamine fiber was measured
using Image J software (NIH, Bethesda, MD, USA). The optical density of three
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different fields from each section within equal area in the striatum were used for
analysis.
2.7 Immunofluorescence and Confocal Microscopy
Brain sections were washed with 0.01 M phosphate buffered saline (PBS),
pH 7.4 then incubated with 10% normal goat serum in PBS 0.3% Triton-X 100 for 1
hour at room temperature. The sections were then washed once with 0.01 M PBS
and incubated with primary Mouse monoclonal antibody against TH (TH,
immunostar, 1:1000) and double labeled with Rabbit polyclonal antibody that detects
endogenous levels of phosphorylated α-synuclein (α-synuclein (phospho S129)
abcam, 1:1000) or anti- α-synuclein filament rabbit polyclonal antibody (α-syn
filament, Abcam, 1:2500) or rabbit polyclonal anti-GFAP antibody (GFAP, Abcam,
1:1000). Iba1 was stained using primary antibody rabbit polyclonal anti-Iba1 (Iba1,
Wako, MA, USA 1:1000). Sections that stained with α-synuclein filament and GFAP
were previously treated with antigen retrieval (Proteinase K 5 µg/ml for 30 minutes
at 25°C). After two days sections were washed with 0.01 M PBS several times.
Then, the sections were incubated overnight with corresponding secondary antibody
anti-mouse Alexa 488 (1:1000), anti-rabbit Alexa 594 (1:1000). After washing,
sections were mounted on slide using (Fluoroshield mounting medium, Sigma) then
the images were acquired in confocal microscope (Nikon EZC1). For detecting the
pathological accumulation of α-synuclein within the TH neurons of three sections
from each animal were selected from the following anatomical location -2,82 mm,
-3,1 mm and -3,38 mm relative to bregma.
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2.8 Stereology
Stereology is the method of choice to quantify number of cells from the
histological samples. It provides three dimensions (3D) unbiased interpretation for a
two dimensions (2D) cross sections. To estimate the number of TH neurons in the
SNpc area, we used optical fractionator of the stereo Investigator system (version
2018). Briefly, seven serial coronal sections from the SNpc area of each animal were
counted following the manufacturer’s instruction. The thickness of the sections were
measured with a z-axis microcreator. The counting contour was outlined with a 5x
objective and then 63x objective was used for counting (Haque et al., 2012). The
results are presented in number and percentage.
2.9 Expression and Purification of Recombinant Human α-synuclein
The expression vector pT7-7 wt-α-synuclein (pT7-7 wt-α-synuclein was a
gift from Hilal Lashuel, Addgene plasmid # 36046) was transformed with E. coli
strain BL-21 DE-3cells , and expression was induced by the addition of isopropyl D–
thiogalactopyranoside (IPTG). Cells were harvested, resuspended in non-denatured
lysis buffer (PBS containing: 5 mM EDTA, 0.02% Sodium Azide) and then
homogenized by glass homogenizer and followed by sonication for 10 minutes. The
cell resuspension was then boiled for 10 minutes and then cooled on ice for 30
minutes. The cell lysate was then centrifuged at 15 K for 20 minutes, the supernatant
was then dialyzed against gel filtration buffer (10 mM Tris pH 7.6, 50 mM NaCl, 1
mM EDTA, 1 mM PMSF), then the lysate was filtered using 0.22 um filters and
concentrated (2-4 mL/L of cell culture) using protein concentration columns
(MWCO 7 K). The concentrated lysate was injected into gel filtration column
Superdex 200 and the fractions were collected and examined by SDS gel and the
selected fractions were pooled, and the concentration was estimated by BCA assay.
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2.10 Generation of α-synuclein Pre-Formed Fibrils (PFF)
100 µM of α-synuclein were incubated at 37°C for 7 days. During this 7 days
α-synuclein were shaken continuously in a Thermomixer (Eppendorf, Germany) at
800 rpm. At different time point samples were collected for Thioflavin-S assay to
monitor the fibril formation. Following that, fibrils were centrifuged at 18,000 g for
10 minutes to collect the insoluble fibrils. Then, the fibrils were fragmented on ice
using ultra-sonication by Sonic ruptor 250, equipped with a fine tip (5-s pulses,
output of 40 watts for 5 minutes) (Karampetsou et al., 2017).
2.11 Western Blot
Western Blot was preformed to confirm the fibril formation. 15 μg of αsynuclein preformed fibril and α-synuclein monomer were loaded in 15% SDSpolyacrylamide gel, electrophoresed, and then proteins were transferred onto a
PVDF membrane and incubated overnight at 4°C with a specific primary mouse
monoclonal antibody syn-1. followed by horseradish peroxidase (HRP)-conjugated
secondary antibody. The protein recognized by the antibody was visualized using a
West Pico chemiluminescence kit (Thermo Scientific, Rockford, IL, USA).
2.12 Statistical Analysis
For Data analysis Graph Pad Prism (InStat software, La Jolla, CA, USA) was
used. Data were analyzed using One-way ANOVA test followed by Dunnett's
Multiple comparison test and Two-way ANOVA was used for behavior study. T-test
was used to estimate the difference between (PBS + MPTP low dose) Vs (PFF +
MPTP low dose) and (PBS+ High dose) Vs (PFF+ High dose). All Data were
presented as mean value ± SEM. Significance was denoted by *P < 0.05, **P < 0.01
and ***P < 0.001.
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Chapter 3: Results
3.1 Characterization of Human α-Synuclein Pre-Formed Fibrils (PFF).
After sonication of the fibril we used immunoblotting to confirm the presence
of high molecular weight aggregate. Smear band of different molecular weights
species was detected which indicate the formation of α-Synuclein with different
molecular weights (Figure 6).

-150 KDa
-100 KDa
-75 KDa
-50 KDa
-37 KDa
-25 KDa
-20 KDa
-15 KDa

Figure 6: Characterization of human α-synuclein pre-formed fibrils (PFF).
Immunoblotting show a smear of different molecular weight species.
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3.2 Low Dose of MPTP (10 mg/kg.b.wt) Enhances the Spreading of α-Synuclein
from the Injection Site to the SNpc while the Spreading Decrease with High
Dose (25 mg/kg.b.wt) of MPTP
MPTP has been known to cause dopamine neurons death and being used as a
neurotoxin model of PD in animal. However, MPTP does not contribute to Lewy
body like pathology in mice. It is not clear at the moment the reason of this
inconsistency. To examine whether MPTP has any role in α-synuclein accumulation
and spreading, we have attempted the current experiment. In the current study, we
have used two different doses of MPTP. We have performed stereotaxic injection to
deliver 5 μg α-synuclein PFP to the mouse right dorsal striatum. Six weeks after, we
have challenged the animal with MPTP with two different doses (25 mg/Kg.b.wt and
10 mg/Kg.b.wt) once daily for 5 consecutive days. At the end of two weeks after the
start of MPTP, we collected the brain and performed the immunohistochemical
analysis using antibody that detect α-synuclein as phospho-ser129. At the site of
injection, we found that phospho-ser129 significantly detected in the animal injected
with wild type α-synuclein PFF in presence of saline or low dose of MPTP.
However, we did not observe phospho-ser129 syn in the contralateral side nor in
animal injected with PBS (Figure 7). This result suggests that PFF can induce the
expression endogenous α-synuclein irrespective of MPTP exposure. Interestingly,
we observed that the pS129 α-synuclein antibody showed consistently more severe
and widely distributed immunoreactivity in the mice inoculated with α-synuclein and
further challenged with low dose of MPTP. However, intrastriatal PBS injected mice
challenged with MPTP or saline did not show any detectable pS129 α-syn
immunoreactivity within the experimental time period suggesting that induction of
endogenous α-synuclein requires PFF as seeding material.

43
SNpc neurons projected their nerve terminal to striatum. We were interested
to examine whether the exogenous α-synuclein PFF also triggers the spreading from
injection site to cell body. We have injected MPTP to α-synuclein preformed fibrils
injected mice to examine whether it could further accelerate the rapid propagation
and more robust α-synuclein pathology in the interconnected brain areas such as
dopamine neurons of SNpc. We have performed double immunofluorescence
staining of TH and pS129 syn. We have detected cytoplasmic accumulation of
pS129 syn surrounding the nucleus of the neuron that stained positively with TH in
animal injected with α-synuclein PFF and received saline or low dose of MPTP
(Figure 8). Surprisingly, we found that the spreading of α-synuclein was
significantly lower in animals that received α-synuclein PFF along with high dose of
MPTP (Figure 8). Moreover, the accumulation of α-synuclein was only detected in
SNpc in the ipsilateral side of all groups of PFF injected animals (Figure 8). Further,
we have counted the number of TH neurons in the SNpc area in a similar anatomical
location which was stained positive with pS129-syn. We observed significant
colocalization and accumulation of pS129-syn in the TH neurons of PFF injected
animal with low dose of MPTP (Figure 9, 10). Taken together, our result suggests
that low dose of MPTP enhances the spreading and accumulation of α-synuclein.
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Figure 7: Photomicrograph of coronal section of striatum stained with antibody to
detect endogenous phosphorylated serine 129 α-Synuclein. The image showing a
detectable level of phosphorylated α-synuclein at the injection site in animals
received intrastriatal injection of wild type α-synuclein PFF. Scale Bar represent 50
µm.
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Figure 8: Image of coronal section at SNpc. The image showing section of SNpc
stained with antibody detects the endogenous level of phosphorylation at serine 129
α-Synuclein (green) and TH antibody (red). The image showing the spreading of
phosphorylated α-Synuclein with saline and low dose of MPTP. very weak spreading
was detected with High dose of MPTP. Scale Bar represent 30 µm.
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Figure 9: Higher magnification of image showing coronal sections at SNpc stained
with antibody that detects the endogenous level of phosphorylation at serine 129 αSynuclein (green) and TH antibody (red). The image showing the spreading of
phosphorylated α-Synuclein with saline and low dose of MPTP. very weak spreading
was detected with the high dose of MPTP. Scale Bar represents 50 µm.
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Figure 10: Bar graph showing the number of TH neurons that contains phosphorylated α-synuclein at the SNpc. Data represent mean value
± SEM. Differences were estimated using one-way ANOVA followed by Dunnett's Multiple Comparison Test. *P < 0.05, **P < 0.01 and
***P < 0.001
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3.3 Low Dose of MPTP Enhances the Proteinase-k Resistant Cytoplasmic α-syn
Aggregation where High Dose of MPTP Enhances Nuclear
Translocation in α-syn Injected Mice.
To further characterize whether the observed accumulation of α-synuclein in
the SNpc is truly representing the pathogenic form of α-synuclein, we performed
proteinase K (PK) treatment of the brain section for 30 minutes at 25°C and stained
with an α-synuclein conformational specific antibody that recognizes the α-synuclein
filament. We observed the α-synuclein accumulation within the TH neuron in PFF
inoculated animals treated with saline or low dose of MPTP (Figure 11). Similar to
pS129 synuclein staining, we found, that the PFF inoculated animal injected with the
low dose of MPTP showed a higher accumulation of α-synuclein within the TH
positive neurons compared with the saline treated animals. We also found that PFF
inoculated animals with the high dose of MPTP the accumulation of α-synuclein in
the TH positive neuron was significantly lower compared with animals treated with
saline (Figures 11,12,14). As expected, accumulation of conformation specific αsynuclein was not detected in SNpc in the contralateral side of all groups of PFF
injected animals (Figure 11) or in the ipsilateral side of animal injection with PBS
(Figure 13). Interestingly using α-synuclein conformation specific antibody, we have
detected two different types of signals. A cytoplasmic signal accumulated around
the nucleus and nuclear accumulated staining (colocalized with the nuclear specific
stain too pro). In animals inoculated with α-synuclein PFF and treated with the
saline, the majority of the signal was localized in the cytoplasm surrounding the
nucleus (Figure 15). In animals inoculated with α-synuclein PFF and received the
low dose of MPTP, two types of signals were detected the nuclear accumalated
signal and cytoplasmic signal that surrounds the nucleus (Figure 15). In oppose to

49
low dose of MPTP, high dose group, the majority of the signals appeared at the
nucleus (Figure 15).
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Figure 11: Image of coronal sections at SNpc stained with antibody recognizes the αSynuclein filament (green) and TH antibody (red). The image showing the spreading
of α-synuclein with saline and the low dose of MPTP. very weak spreading was
detected with the high dose of MPTP. Scale Bar represent 30 µm.
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Figure 12 : Higher magnification of image showing coronal sections at SNpc stained
with antibody recognizes the α-synuclein filament (green) and TH antibody (red).
The image showing the spreading of α-synuclein with saline and the low dose of
MPTP. very weak spreading was detected with the high dose of MPTP. Scale Bar
represent 50 µm.
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Figure 13: Image of coronal sections at SNpc stained with antibody recognizes the αsynuclein filament (green) and TH antibody (red). The image showing that no
spreading of α-synuclein was detected in animals receives intrastriatal injection of
PBS. Scale Bar represent 30 µm.
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Figure 14: Bar graph showing the number of TH neuron that stained with α-synuclein filament antibody at the SNpc. Data represent mean
value ± SEM. Differences were estimated using one-way ANOVA followed by Dunnett's Multiple Comparison Test. *P < 0.05, **P < 0.01
and ***P < 0.001
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Figure 15: Image of coronal at SNpc with Too pro (blue), TH antibody (red) and
antibody recognizes the α-synuclein filament (green). Orang arrow pointing the
cytoplasmic accumulation surrounding the nucleus of α-synuclein filament. White
arrow pointing the nuclear localization of α-synuclein. Scale Bar represent 50 µm.
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3.4 Activation of Astrocyte and Microglia in the Animal Inoculated with PFF
and Treated with MPTP
It has been documented that neuroinflammation plays a critical role in the
pathophysiology of PD. The activation astrocyte and microglia have been considered
as marker of neuroinflammation which progresses to cause neurodegeneration.
Hence, we examined the activation of astrocyte and microglia by staining with Iba-1
and GFAP respectively. Using GFAP and Iba-1 staining, we found that high dose of
MPTP causes significant increase in the number of activated microglia and astrocyte
in the SNpc area whether the animals were injected with α-synuclein PFF or not.
This activation was more profound when α-synuclein PFF inoculated mice were
exposed to high dose of MPTP. Moreover, some of microglia appeared as ameboid
shape (Figures 16-20). However, we observed subtle increase in activation of GFAP
in animals that received the low dose of MPTP in with or without the α-synuclein
PFF injection (Figures 16-18). Mice those inoculated with PFF showed higher
activation of microglia as counted by Iba-1 staining comparing with PBS injected
control animal. This activation did not further increase in the presence of low dose
MPTP (Figures 19, 20).

55

WT-syn
+ Saline

WT-syn
+ Low dose

WT-syn
+ High dose

GFAP

TH

Merge

Figure 16: Image of coronal section of wt-synuclein PFF injected animal at SNpc
stained with GFAP antibody (green) and TH antibody (red). The image showing a
significant increase in Astrocyte activation in the SNpc area in high dose group.
Scale Bar represent 30 µm.
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Figure 17: Image of coronal section of PBS injected animal at SNpc stained with
GFAP antibody (green) and TH antibody (red). No significant difference in
Astrocyte activation in the SNpc area among the groups. Scale Bar represent 30 µm.
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Figure 18: Bar graph showing the number of astrocytes per field at the SNpc. Data represent mean value ± SEM. Differences were estimated
using one-way ANOVA followed by Dunnett's Multiple Comparison Test. *P < 0.05, **P < 0.01 and ***P < 0.001
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Figure 19: Image of coronal section at SNpc stained with Iba-1 antibody (green). A significant increase in the number of activated microglia in
the SNpc area in animals injected wt-synuclein PFF and MPTP high dose. Green arrow pointing ameboid shape microglia. Scale Bar represent
50 µm.
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Figure 20: Bar graph showing the number of microglia per field at the SNpc. Data represent mean value ± SEM. Differences were estimated
using one-way ANOVA followed by Dunnett's Multiple Comparison Test. *P < 0.05, **P < 0.01 and ***P < 0.001
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3.5 MPTP Enhances Neurodegeneration in Nigrostriatal Pathways in Mice
Inoculated with PFF
Next, we have counted the dopamine neurons in the SNpc to examine if there
any role of α-synuclein spreading to augment the toxicity. We have used unbiased
stereo investigator system to count the total number of dopaminergic neurons in the
SNpc area. MPTP at high dose (25 mg/kg.b.wt) is known to degenerate
dopaminergic neurons (45-50% DA neurons). The animal that received PFF and
injected with high dose of MPTP showed more DA neuronal death compared to
MPTP only exposure (Figures 21, 22). As expected, low dose of MPTP has very
subtle effect on dopamine neuron death which is non-significant comparing to saline
treated animals (8%). Interestingly, the animal that received PFF and challenged
with low dose of MPTP showed significant loss of Dopamine neurons (33%). Taken
together, this result suggests that presence of PFF significantly enhances the toxicity
of MPTP although high dose of MPTP itself did not show spreading endogenous αsynuclein. The dopamine neurons in the SNpc area projected their nerve ending at
the striatum. Thus, the neurodegeneration seen in the SNpc area must be correlated
with the loss of nerve terminal in the striatum. To confirm this, we performed
dopamine transporter staining at the striatum and presented as intensity (Figures 22,
23). We observed a significant decrement of DAT in the striatum when treated with
high dose of MPTP. This decrease is further augmented in the presence of PFF
which supports TH counting data. We also observed significant reduction in the
signal in animals received both α-synuclein PFF along with low dose of MPTP. Low
dose of MPTP or α-synuclein PFF alone causes only very mild reduction in the
intensity of the signal (Figures 23, 24)
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Figure 21: Coronal sections at the SNpc show immunostaining of tyrosine hydroxylase (TH). The MPTP exaggerates the neurotoxic effect of
α-syn PFF. Scale Bar represents 400 µm.
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Figure 22: Bar graph showing the estimated number of TH neurons at the SNpc using unbiased stereological counting. The MPTP exaggerates
the neurotoxic effect of α-synuclein PFF. Data represent mean value ± SEM. Differences were estimated using one-way ANOVA followed by
Dunnett's Multiple Comparison Test. T-test was used to estimate the difference between (PBS + MPTP low dose) Vs (PFF + MPTP low dose)
and (PBS+ High dose) Vs (PFF+ High dose). *P < 0.05, **P < 0.01 and ***P < 0.001
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Figure 23: Coronal sections at the striatum show immunostaining of dopamine transporter (DAT). The MPTP exaggerates the neurotoxic effect
of α-syn PFF. Scale Bar represents 400 µm.
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Figure 24: Bar graph shows the intensity of the DAT signal at the striatum. The MPTP exaggerates the neurotoxic effect of α-synuclein PFF.
Data represent mean value ± SEM. Differences were estimated using one-way ANOVA followed by Dunnett's Multiple Comparison Test. Ttest was used to estimate the difference between (PBS + MPTP low dose) and (PFF + MPTP low dose). *P < 0.05, **P < 0.01 and ***P <
0.001
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3.6 Motor Activity of the Animal MPTP on α-synuclein PFF Cause Deficit in
Motor Activity.
Lastly, we extended our experiment to examine motor activity of the animals
that received MPTP and pre-inoculated with α-synuclein PFF. We preformed
Rotarod test to assess the motor coordination of the mice and grip test to assess the
muscle strength before and after the MPTP injection. In animal that received high
dose of MPTP along with α-synuclein PFF or PBS showed significant reduction in
the time of falling from the Rotarod. Animal that received low dose MPTP or αsynuclein PFF alone doesn’t show any deficiency in the mice performance in
Rotarod test (Figure 25). However, mice that received both α-synuclein PFF and low
dose of MPTP showed a significant deficit in Rotarod test (Figure 25). However, in
the Grip test assay, we have not observed any detectable change among all the
groups tested (Figure 26).
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Figure 25: Bar graph shows the time of the falling in Rotarod test. The MPTP exaggerates the neurotoxic effect of α-synuclein PFF. Data
represent mean value ± SEM. Differences were estimated using Two-way ANOVA. *P < 0.05, **P < 0.01 and ***P < 0.001
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Figure 26: Bar graph showing the grip strength in Grip test. No significant difference was detected among the groups. Data represent mean
value ± SEM. Differences were estimated using Two-way ANOVA.
*P < 0.05, **P < 0.01 and ***P < 0.001
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Chapter 4: Discussion
α-synuclein is a 14 kDa soluble naturally unfolded protein mainly present in
the presynaptic terminal of the neurons. Cytoplasmic accumulation of misfolded αsynuclein as Lewy body is a pathological hallmark of both sporadic and familial
form of PD (Farrer, 2006). Point mutations of SNCA gene as well as duplication or
triplication of SNCA gene have been reported in PD patients in several families. The
physiological function of α-synuclein is not fully understood. However, it has shown
that germ line deletion of α-synuclein in mice impairs neurotransmitter release.
Moreover, α-synuclein deficient mice are resistant to mitochondrial neurotoxin,
MPTP (Fountaine & Wade-Martins, 2007). However, the data related to α-synuclein
aggregation in MPTP injected mice is conflicting (Meredith et al., 2002; Purisai et
al., 2005; Shimoji et al., 2005). It has been reported that MPTP acute exposure in
mice does not lead to any Lewy body like pathology although profound
dopaminergic neurodegeneration is observed (Shimoji et al., 2005). One report
demonstrated the increased expression of mRNA in mice that received chronic
MPTP (Purisai et al., 2005). Moreover, Meredith et al. (2002) provided evidence that
MPTP injection builds up granular and filamentous α-synuclein inclusions in the
dopaminergic neurons. However, others negated such claim and reported that MPTP
causes neurodegeneration without α-synuclein inclusion (Shimoji et al., 2005). It is
noteworthy that different doses of MPTP have been used in mice to model PD such
as acute, subchronic and chronic. The MPTP dose used in these studies seems very
high and causes very similar loss of dopamine. Interestingly, chronic dose of MPTP
only increases the mRNA but not the acute dose. Thus, lack of α-synuclein inclusion
in MPTP mouse model is the major weak point of this model. Although, only
monkeys injected with MPTP have shown intraneuronal inclusions, reminiscent of
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LBs (Forno et al., 1986; Kowall et al., 2000). Moreover, low dose of MPTP in
monkey has been shown to produce greater loss of DA nerve terminals in the
putamen than in the caudate nucleus (Blesa et al., 2010; Moratalla et al., 1992).
Thus, one of the arguments can be raised that this discrepancy is because of the
species of animal, dose or duration of MPTP been used in these models.
Recently, it has been demonstrated that amyloid fibrils have “prion-like”
property and can be propagated from one brain region to other interconnected brain
regions. Growing number of experimental data suggests that inoculation of
pathological form of α-synuclein such as PFF in mice induces endogenous αsynuclein propagation and spreading progressively throughout the interconnected
brain regions by cell to cell transmission mechanism (Bernis et al., 2015; Luk et al.,
2012; Paumier et al., 2015; Recasens et al., 2014). However, this α-synuclein
propagation requires the presence of endogenous α-synuclein since α-synuclein
knockout mice failed to show such spreading and aggregation (Luk et al., 2012). The
transgenic mice expressing WT or mutant α-synuclein do not initiate the propagation
by itself indicating that PFF injection as seeding material is prerequisite. Thus, αsynuclein fibrils mediated seeding process seems to be very important steps for
propagation. The α-synuclein propagation only has been observed by pS129 α-syn
antibody and thus hyper-phosphorylation of α-synuclein at serine 129 residue is
considered as pathological consequence of α-synuclein species and seems to play
critical role in the aggregation of α-synuclein and PD progression (Paumier et al.,
2015). Previous reports have shown that minimum time required to observe the
spreading and aggregation of α-synuclein in SNpc area is at least month or more
after the inoculation of α-synuclein PFF. However, dopaminergic neuronal death
does not appear before 3 months of post-injection of PFF.
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In the current study, we have asked whether different doses of MPTP (low
and high dose) injection in the mice pre-inoculated with PFF have any effect on
endogenous α-synuclein spreading, toxicity and pathology. To accomplish this goal,
we have performed single stereotaxic delivery of α-synuclein PFF in the striatum of
the mice and challenged them with two different doses of MPTP such as high dose
(25 mg/kg.b.wt) and low dose (10 mg/kg.b.wt). The high dose of MPTP has been
known to cause rapid destruction of the dopaminergic neurons in the nigrostriatal
pathway with concomitant loss of dopamine transporter and is commonly used in
modeling of PD. The Low dose of MPTP has been reported to induce mild effect in
dopamine neurons without significant destruction of the dopaminergic neuron (Lee
et al., 2017). It has been reported that posttranslational modification of α-synuclein
that induced by oxidative stress can decrease α-synuclein solubility and enhance its
oligomerization property which leads to increase the toxicity induced by α-synuclein
in the dopaminergic neuron (Perfeito et al., 2014; Xiang et al., 2013). MPTP after
converted to MPP+ inhibits complex I in mitochondria respiratory chain complex
and generates reactive oxygen species (ROS) selectively in the dopaminergic
neurons (Langston, 2017). We observed that MPTP exposure at low dose
significantly increases the spreading and accumulation of endogenous α-synuclein
from striatum to SNpc as detected by pS129 α-syn antibody. Surprisingly, we
observed that high dose of MPTP reduces α-synuclein spreading from the striatum to
the SNpc and it also decreases the localization of α-synuclein in the cytoplasm. In
vitro study demonstrated that the chemical structure of α-synuclein has the tendency
to become less soluble and form insoluble high molecular weight aggregate when it
exposes to oxidizing agent (Souza et al., 2000). MPTP generates reactive oxygen
species (ROS) and tends to increase the amount of insoluble α-synuclein aggregate.
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Thus, MPTP can intensify this aggregation process (Jethva et al., 2011) and may
produce more detrimental effect on neurons. In our current study, we observed
higher neuronal death due to high dose of MPTP exposure in mice with PFF
injection suggestive less number of healthy dopamine neurons are available for
active spreading of α-synuclein.
A growing body of evidence showed that formation of proteinase-k resistant
α-synuclein species in the human PD brain has the characteristics of
intracytoplasmic inclusion of LBs (Spinelli et al., 2014). To examine this
phenomenon, we performed proteinase-k treatment to brain section before
immunostaining to detect PK resistant aggregated α-synuclein using conformation
specific antibody which previously has been reported (Grassi et al., 2018).
Proteinase-K has also been extensively used to retrieve the antigen in addition to
remove soluble synuclein (Furuoka et al., 2005; Neumann et al., 2002). We found
that proteinase-k resistant α-synuclein were accumulated in the SNpc area of αsynuclein preformed fibrils injected mice with or without MPTP challenge.
However, α-synuclein injected mice challenged with low dose of MPTP reflects
abundant amount of proteinase-k resistant α-synuclein. In addition, we did not
observe α-synuclein positive staining in the SNpc region of control or MPTP alone
injected mice after proteinase-k treatment. Surprisingly, we observed significant
nuclear localization of α-synuclein when α-synuclein PFF injected animals were
treated with high dose of MPTP.
One study using transgenic fruit flies and tissue culture system has shown the
translocation of α-synuclein to nucleus and promotes cell death by inhibiting histone
acetylation where administration of histone deacetylase inhibitor rescued the cells
against α-synuclein toxicity (Kontopoulos et al., 2006). Recently, it has been
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demonstrated that TRIM28 regulates the nuclear accumulation and toxicity of αsynuclein (Rousseaux et al., 2018). Transgenic mice expressing human α-synuclein
has been reported to exhibit nuclear translocation with distinct cytoplasmic inclusion
(Masliah et al., 2005). Recent study found that over expression of α-synuclein can
alter the expression of several genes, including major DNA repair genes and genes
associated with cell cycle checkpoint such as ATM signaling leading to increased
level of phosphorylated p53 and DNA damage (Paiva et al., 2017). It has been
suggested that α-synuclein is a cell cycle regulatory protein that increases
accumulation of mitotic factor cyclin B and down regulates the tumor suppressor
retinoblastoma 2 (RB) leading to apoptosis to postmitotic neurons (Lee et al., 2003).
An important study shows that α-synuclein can enhance double strand DNA repair
by facilitate non-homologous end joining reaction at the damage site (Karampetsou
et al., 2017). Another study showed that α-synuclein promote cell death by activating
nitric oxide synthase (NOS) which leads to DNA damage and activation of poly
(adenosine 5'-diphosphate-ribose) (PAR) polymerase-1 (PARP-1) leading to
parthanatos cell death pathway (Kam et al., 2018). It has been found that the
oxidative stress induced by H2O2 in tissue culture increases nuclear translocation of
α-synuclein leading to increase cell death (Zhou et al., 2013). In our current study,
we have observed the nuclear translocation of PK resistant species of α-synuclein in
high dose MPTP injected PFF inoculated mice which also showed highest DA
neurons death. Our result in agreement with the above mentioned findings and
supports further that α-synuclein mediates pathological effect that leads to
neurodegradation by increasing its nuclear translocation rather than spreading.
Neuroinflammation significantly contributes to neurodegeneration not only in
animal models of PD (Gao et al., 2002) but possibly in PD patient (Imamura et al.,
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2003). α-synuclein aggregation could elicit microglial and astrocytic response that
mediates neuroinflammation by secreting inflammatory mediators such as reactive
oxygen species, cytokines and chemokines that eventually contributes to enhanced
death of dopamine neurons in SNpc area (Glass et al., 2010; Saijo et al., 2009). Mice
over expressing human α-synuclein show an increased level of activated microglia
and levels of TNF-α in the striatum and SNpc area (Watson et al., 2012). It has been
reported that the extracellular α-synuclein released from the neuron produces
microglial inflammatory response by acting as an endogenous agonist for Toll-like
receptor 2 (TLR2) (Kim et al., 2013). A recent study using primary cell culture
demonstrates that soluble and aggregated α-synuclein can be uptaken by
oligodendrocytes without inducing cytotoxicity. However, the same processe
induced cytotocity under oxidative stress condition produced by H2O2. . H2O2
increase the size of α-synuclein aggregates which leads to increase uptake and
induce cytotoxicity (Puka et al., 2014). In mice, MPTP can induce glial response by
activating microglial and astrocyte. Activated microglia in MPTP treated mice has a
larger cell body with shorter and thicker processes while activated astrocyte show a
larger cell body with long and thick processes. Furthermore, mice brain shows an
inflammatory reaction include increase expression of MHC class I and II on
microglia and infiltration of CD41 and CD81 T cells in the striatum and the SNpc
(Kurkowska-Jastrzębska et al., 1999). Consistent with the above report, we found
significant increase in the number of activated astrocyte and microglia in the SNpc
area of mice that received a combination of the high dose of MPTP and α-synuclein
PFF. Noteworthy that in the same group of animal, we observed the highest cell loss
with nuclear translocation of α-synuclein within the TH neurons. A recent study
found that the glial cell including microglia, astrocytes, and oligodendrocytes has a
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major role in regulating synapse (Jebelli et al., 2015). In Alzheimer’s disease (AD)
when the synapse is challenged with soluble β-amyloid (Ab) oligomers microglia
phagocyte the synaptic material which leads to early synapse loss in AD (Hong et
al., 2016). In transgenic mice expressing human α-synuclein immunization of the
mice with human α-synuclein antibody preserve the synaptic density and reduce the
neuropathology of the transgenic mice (Masliah et al., 2005). Synapses are a
specialized structure which allows the neurons to communicate throw releasing
neurotransmitters and the function of the nervous system depend on the correct
communication between the neurons (Jebelli et al., 2015). The prion hypothesis of αsynuclein stated that the α-synuclein can be up-taken by neurons where it acts as
seed and enhances the aggregation of endogenous α-synuclein and then releases into
the extracellular space. Aggregated α-synuclein then enters the neighboring neuron,
microglia or astrocyte (Brundin & Melki, 2017; Lee et al., 2008; Lee et al., 2010).
When Astrocytes uptake α-synuclein by endocytosis α-synuclein cause changes in
gene expression which leads to increase induction of pro-inflammatory cytokines
and chemokines which lead to inflammatory response mediate the pathological
effect (Lee et al., 2010). We observed increased number of activated astrocytes in
the SNpc of α-synuclein injected mice compared to control. This activation became
higher when we combined α-synuclein PFF with high dose of MPTP. MPTP is a
mitochondrial complex I inhibitor and plays a key role in the massive release of free
radicals following intraperitoneal administration to rodents. Collectively, aggregated
α-synuclein and the high dose of MPTP could be able to enhance the activation of
the glial cell and amplified the cascade of nigrostriatal degeneration (Figure 27).
Finally, we performed behavioral studies with our experimental mice. We
could further demonstrate that PFF inoculated mice that challenged with MPTP not
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only affect the neurons in SNpc but also compromised their behavior as measured by
rotarod test. However, we have not observed any significant change in grip test
among the group tested comparing to PBS injected and saline treated animals. In
summary, we provided data showing significant spreading of α-synuclein and
moderate dopamine neurons loss in mice injected with low dose of MPTP in
conjunction with α-synuclein PFF. Thus, combination low dose of MPTP with PFF
inoculated animals can be used future mechanistic study and novel drug
development.
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Figure 27: Data Discussion. A. Low dose of MPTP leads to generation of ROS in the
dopaminergic neuron. ROS cause changes in α-synuclein structure which initiates
the transformation of α-synuclein to a less soluble form. Aggregate of α-synuclein
has the ability to spread to other neurons which lead to slow onset and propagation
of the disease. B. High dose of MPTP lead to generation of ROS in the dopaminergic
neuron and activation of glial cells. Glial cells uptake α-synuclein from the synaptic
cleft which lead to production of proinflammatory cytokine and ROS that lead to
rapid dopamine neuron death.
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Chapter 5: Conclusion
5.1 Summary
Our study indicates that injection of low dose of MPTP in mice inoculated
with α-synuclein PFF has a higher ability to enhance the spreading of endogenous αsynuclein from the injection site to interconnected brain region such as SNpc. This
α-synuclein spreading has been considered as an early event of PD. Surprisingly, we
did not observe spreading of endogenous α-synuclein when high dose of MPTP is
employed in the mice that received an intrastriatal injection of α-synuclein PFF.
However, we have observed significantly higher loss of dopaminergic neurons in the
SNpc and altered motor coordination. We also found that in this group of animals
exhibited higher activation of glial cells (microglia and astrocytes). We didn’t detect
a similar pattern of activation in animals that receive a combination of the low dose
of MPTP and intrastriatal injection of α-synuclein PFF. Because of enhancement of
α-synuclein spreading and moderate dopamine neurons death in low dose of MPTP
with PFF, our presented model may be used to study further the mechanism of αsynuclein mediated toxicity and for screening of potential drug for PD by tracking
spreading of α-synuclein.
5.2 Future Study
Future studies will be needed to investigate the role of glial cells in PD and
synucleinopathy and to understand more the precise mechanism by which low dose
of MPTP induces more spreading of endogenous α-synuclein and its relevance with
synucleinopathy related to Parkinson’s disease.
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